Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01690520 · ClinicalTrials.gov registry record · Phase 2
Donor Umbilical Cord Blood Transplant With or Without Ex-vivo Expanded Cord Blood Progenitor Cells in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, or Myelodysplastic Syndromes
A Phase 2 study, sponsored by Nohla Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 163
- Enrollment target
NCT01690520 is a Phase 2 study that has completed, run by Nohla Therapeutics. The registered enrollment target is 163 participants.
The verdict
NCT01690520, a Phase 2 study, has completed, sponsored by Nohla Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 163 participants
- Enrollment target
Study Summary
This randomized phase II trial studies how well donor umbilical cord blood transplant with or without ex-vivo expanded cord blood progenitor cells works in treating patients with acute myeloid leukemia, acute lymphoblastic leukemia, chronic myelogenous leukemia, or myelodysplastic syndromes. Giving chemotherapy and total-body irradiation before a donor umbilical cord blood transplant helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's cells. When the healthy stem cells and ex-vivo expanded cord blood progenitor cells are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. It is not yet known whether giving donor umbilical cord blood transplant plus ex-vivo expanded cord blood progenitor cells is more effective than giving a donor umbilical cord blood transplant alone.
Interventions
- DRUG Cyclophosphamide
- DRUG Mycophenolate Mofetil
- DRUG Fludarabine Phosphate
- DRUG Cyclosporine
- BIOLOGICAL Ex Vivo-Expanded Cord Blood Progenitor Cell Infusion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 163 participants |
| Start Date | 2012-12-11 |
| Est. Completion | 2020-05-29 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01690520
The ClinicalTrials.gov registry entry for NCT01690520 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 163 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nohla Therapeutics, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT01690520 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01690520 about?
NCT01690520 is a clinical study titled "Donor Umbilical Cord Blood Transplant With or Without Ex-vivo Expanded Cord Blood Progenitor Cells in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, or Myelodysplastic Syndromes". This randomized phase II trial studies how well donor umbilical cord blood transplant with or without ex-vivo expanded cord blood progenitor cells works in treating patients with acute myeloid leukemia, acute lymphoblastic leukemia, chronic myelogenous leukemia, or myelodysplastic syndromes. Giving ...
What is the current status of trial NCT01690520?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 163 participants. The study started on 2012-12-11. Estimated completion is 2020-05-29.
What interventions are being tested in trial NCT01690520?
The interventions under investigation include: Cyclophosphamide (DRUG), Mycophenolate Mofetil (DRUG), Fludarabine Phosphate (DRUG), Cyclosporine (DRUG), Ex Vivo-Expanded Cord Blood Progenitor Cell Infusion (BIOLOGICAL).
Who is sponsoring clinical trial NCT01690520?
This trial is sponsored by Nohla Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.